SCHEMBL3480207

SCHEMBL3480207

COC(=O)COc1c(OCC(=O)OC)c(F)c2sccc2c1F

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.47
MEN1 O00255 1/20 0.47
CYP1A2 P05177 1/20 0.47
KDM4E B2RXH2 3/20 0.37
ALDH1A1 P00352 2/20 0.35
MAPT P10636 2/20 0.35
HSD17B10 Q99714 1/20 0.35
LMNA P02545 1/20 0.35
CXCR1 P25024 2/20 0.34
CXCR2 P25025 2/20 0.34
PTGS2 P35354 1/20 0.34
SYK P43405 3/20 0.33
JAK2 O60674 1/20 0.33
MMP1 P03956 1/20 0.33
MMP9 P14780 1/20 0.33
MMP8 P22894 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3484064 0.84 CD69 (0.42) KMT2AKDM4EALDH1A1SMN1; SMN2
SCHEMBL3480388 0.74 MAPT (0.34) KDM4EALDH1A1MAPTHSD17B10SMN1; SMN2
SCHEMBL3480427 0.73 KMT2A (0.37) KMT2AMEN1CYP1A2KDM4EALDH1A1
SCHEMBL3480358 0.72 KMT2A (0.36) KMT2AMEN1CYP1A2KDM4EALDH1A1
SCHEMBL3480301 0.71 DYRK1A (0.30)
SCHEMBL3480323 0.71 DYRK1A (0.30)
SCHEMBL3483177 0.70 HSD17B10 (0.38) KDM4EALDH1A1MAPTHSD17B10SMN1; SMN2
SCHEMBL4832334 0.68 SMN1; SMN2 (0.43) KMT2AMEN1CYP1A2KDM4EALDH1A1
SCHEMBL30594131 0.68 MMP1 (0.49) KMT2AMEN1CYP1A2KDM4EALDH1A1
SCHEMBL21883673 0.68 MMP1 (0.49) KMT2AMEN1CYP1A2KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100317625-A1 NOVEL SULFONAMIDOMETHYLPHOSPHONATE INHIBITORS OF BETA-LACTAMASE 92229129 QUEBEC INC. (CA) 2010-12-16 US disclosed
EP-2024376-A1 NOVEL SULFONAMIDOMETHYLPHOSPHONATE INHIBITORS OF BETA-LACTAMASE Merck & Co., Inc. (US) 2009-02-18 EP disclosed
WO-2007139729-A1 NOVEL SULFONAMIDOMETHYLPHOSPHONATE INHIBITORS OF BETA-LACTAMASE MERCK & CO., INC. (US) 2007-12-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317625-A1 NOVEL SULFONAMIDOMETHYLPHOSPHONATE INHIBITORS OF BETA-LACTAMASE MGAM, BPGM, PPME1 KMT2A 2187/4885MEN1 3104/4885CYP1A2 2728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.